Fidson Healthcare Plc, a leading Nigerian pharmaceutical company, has been selected to develop and manufacture a generic version of Roche's influenza antiviral drug, baloxavir marboxil. This was made possible through a licensing arrangement backed by the Medicines Patent Pool, a global organization that facilitates access to affordable medicines. The deal is a significant milestone for Fidson, placing the company among a small group of global manufacturers chosen for the programme.
The journey to this achievement began with Fidson founder Fidelis Ayebae's unconventional educational background. Ayebae earned a Higher National Diploma in Civil Engineering in 1976 and later added an Advanced Diploma in Business Administration from the University of Lagos. Before founding Fidson in 1995, Ayebae spent years working at Citibank. This unique blend of engineering, business, and banking experience has contributed to Fidson's success in the pharmaceutical industry.
Fidson's achievements in the pharmaceutical sector are noteworthy. The company became the first West African manufacturer of indigenous antiretroviral drugs for HIV, as well as proton pump inhibitors and complex infusion formats. This technical record has made Fidson a credible partner for international deals. The company's revenue has also grown significantly, becoming the first Nigerian pharmaceutical company to cross N100 billion in revenue, eventually reaching past N119 billion.
Fidson's growth can be attributed to years of reinvestment in plants, regulatory systems, and staff. The company has also formed global partnerships to expand its capabilities. For instance, Fidson worked with Japan's Ohara Pharmaceutical Company on an oncology expansion and with three Chinese consortiums on an HIV-focused manufacturing hub in the Lekki Free Trade Zone. These partnerships have added to Fidson's track record, which regulators rely on to assess the company's credibility.
Under the Roche arrangement, Fidson will receive technical information and reference materials needed to pursue regulatory approval. The aim is to make the drug available in eligible markets at a lower cost. This partnership is expected to increase access to affordable medicines for people in Nigeria and other eligible markets.
Fidson's achievement is also a recognition of Ayebae's contributions to the pharmaceutical industry. In 2025, Ayebae became the youngest person to receive the Nigeria Academy of Pharmacy's Lifetime Achievement Award. This award came nine years after he became the first non-pharmacist admitted into the Pharmaceutical Society of Nigeria's Hall of Honorary Membership.
The partnership between Fidson and Roche is a significant step forward in increasing access to affordable medicines in Nigeria and other eligible markets. With Fidson's expertise in manufacturing and Roche's support, the generic version of baloxavir marboxil is expected to be available at a lower cost, making it more accessible to people who need it.
Key points
- Fidson Healthcare partners with Roche to develop generic version of influenza antiviral drug baloxavir marboxil
- Fidson becomes one of a small group of global manufacturers chosen for the programme
- The partnership aims to make the drug available in eligible markets at a lower cost
